NCI-H1573細(xì)胞

是否是腫瘤細(xì)胞： 0

物種來(lái)源： 人

年限： stage 4

器官來(lái)源： 肺

ATCC Number： CRL-5877?

相關(guān)**： 腺癌

運(yùn)輸方式： 凍存運(yùn)輸

生長(zhǎng)狀態(tài)： 貼壁生長(zhǎng)

數(shù)量： 大量

Designations: NCI-H1573 [H1573]

NCI-H1573細(xì)胞Depositors: AF Gazdar, JD Minna

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology:

Source: Organ: lung

Tumor Stage: stage 4

Disease: adenocarcinoma

Derived from metastatic site: soft tissue

Permits/Forms:NCI-H1573細(xì)胞 In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.

DNA Profile (STR): Amelogenin: X

CSF1PO: 10,12

D13S317: 11,13

D16S539: 12

D5S818: 11,13

D7S820: 9,11

THO1: 6

TPOX: 8,11

vWA: 17,18

Age: NCI-H1573細(xì)胞35 years

Gender: female

Ethnicity: Caucasian

Comments: The line was established in December 1986.

The patient received prior radiation therapy.

The patient was a smoker.

15 pack years.

Propagation: ATCC complete growth medium: ACL-4 medium (serum-free)

The base medium for this cell line is ATCC formulated DMEM: F12 Medium Catalog No. 30-2006. To make the complete growth medium, add the following components to the base medium:

0.02 mg/ml insulin

0.01 mg/ml transferrin

25 nM sodium selenite (final conc.)

50 nM Hydrocortisone (final conc.)

1 ng/ml Epidermal Growth Factor (do not filter)

0.01 mM ethanolamine (final conc.)

0.01 mM phosphorylethanolamine (final conc.)

100 pM triiodothyronine (final conc.)

0.5% (w/v) bovine serum albumin (final conc.)

0.5 mM sodium pyruvate (final conc.)

extra 2mM L-glutamine (for final conc. of 4.5mM)

Temperature: 37.0°C

Atmosphere: air, 95%; carbon dioxide (CO2), 5%

Subculturing: Protocol: NCI-H1573細(xì)胞Volumes used in this protocol are for 75 sq cm flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.

Remove and discard culture medium.

Briefly rinse the cell layer with Ca++/Mg++ free Dulbecco's phosphate-buffered saline (D-PBS) or 0.25% (w/v) Trypsin - 0.53 mM EDTA solution .

Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 minutes).

Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37C to facilitate dispersal.

Add 2.0 to 3.0 ml of complete growth medium and aspirate cells by gently pipetting.

Transfer cell suspension to a centrifuge tube and spin at approximately 125 X g for 5 to 10 minutes. Discard supernatant.

Resuspend the cell pellet in fresh growth medium. Add appropriate aliquots of the cell suspension to culture vessels.

Incubate cultures at 37C.

Subcultivation ratio: A subcultivation ratio of 1:2 to 1:3 is recommended.

Preservation: Freeze medium: RPMI 1640 medium 85%; fetal bovine serum, 10%; DMSO or complete culture medium described above supplemented with 7.5% (v/v) DMSO

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2006

References: 23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.